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State-of-the-Art PaperCurrent Status of Rotational Atherectomy
Matthew I. Tomey, MD, Annapoorna S. Kini, MD, Samin K. Sharma, MD
New York, New YorkRotational atherectomy facilitates percutaneous coronary intervention for complex de novo lesions with
severe calciﬁcation. A strategy of routine rotational atherectomy has not, however, conferred reduction
in restenosis or major adverse cardiac events. As it is technically demanding, rotational atherectomy is
also uncommon. At this 25-year anniversary since the introduction of rotational atherectomy, we sought
to review the current state-of-the-art in rotational atherectomy technique, safety, and efﬁcacy data in the
modern era of drug-eluting stents, strategies to prevent and manage complications, including slow-ﬂow/
no-reﬂow and burr entrapment, and appropriate use in the context of the broader evolution in the
management of stable ischemic heart disease. Fundamental elements of optimal technique include
use of a single burr with burr-to-artery ratio of 0.5 to 0.6-rotational speed of 140,000 to 150,000 rpm,
gradual burr advancement using a pecking motion, short ablation runs of 15 to 20 s, and avoidance
of decelerations >5,000 rpm. Combined with meticulous technique, optimal antiplatelet therapy,
vasodilators, ﬂush solution, and provisional use of atropine, temporary pacing, vasopressors, and
mechanical support may prevent slow-ﬂow/no-reﬂow, which in contemporary series is reported in 0.0%
to 2.6% of cases. On the basis of the results of recent large clinical trials, a subset of patients with complex
coronary artery disease previously assigned to rotational atherectomy may be directed instead to medical
therapy alone or bypass surgery. For patients with de novo severely calciﬁed lesions for which rotational
atherectomy remains appropriate, referral centers of excellence are required. (J Am Coll Cardiol Intv
2014;7:345–53) ª 2014 by the American College of Cardiology FoundationThe year 2012 marked the 25th year since Jerome
Ritchie, David Auth, and colleagues (1) introduced
rotational atherectomy (RA) as a technique for the
endovascular treatment of obstructive atheroscle-
rotic disease. RA emerged in the 1990s as one of
several tools to treat luminal obstruction via physical
removal of plaque. Although initially explored as
an alternative to balloon angioplasty, RA proved
complementary, facilitating angioplasty and, later,
stenting of complex lesions, particularly those
affected by heavy calciﬁcation. Beyond immediate
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December 5, 2013, accepted December 19, 2013.a consistent long-term beneﬁt of lesion modiﬁ-
cation by RA for restenosis and major adverse
cardiovascular events (MACE). Today, RA use is
infrequent. At one time, RA was involved in up to
10% of percutaneous coronary interventions (PCI)
(2). In more recent series, RA use has fallen to 3%
to 5% in select high-volume centers and <1% in
others (3).
Though uncommon, RA maintains purpose in
the modern cardiac catheterization laboratory. In
the context of recent developments in manage-
ment of stable ischemic heart disease, including
improvement in medical therapy, advances in
design and delivery of drug-eluting stents (DES),
and advances in noninvasive and intravascular
coronary imaging, we sought to review the state-of-
the-art in RA. On the basis of a systematic search
of MEDLINE literature for “rotational atherec-
tomy” and “rotablation,” we reviewed optimal
technique, avoidance and management of compli-
cations, recent data on complications and outcomes
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346of RA with DES, and appropriate application of RA in the
modern cardiac catheterization laboratory.
Principles
RA produces lumen enlargement by physical removal of
plaque and reduction in plaque rigidity, facilitating dilation.
The commercially available Rotablator (Boston Scientiﬁc,
Natick, Massachusetts), invented by Auth and described by
Ritchie and colleagues (4), ablates plaque using a diamond-
encrusted elliptical burr, rotated at high speeds (140,000 to
180,000 rpm) by a helical driveshaft, that advances gradually
across a lesion over a guidewire. The burr preferentially
ablates hard, inelastic material, such as calciﬁed plaque, that
is less able to stretch away from the advancing burr than is
healthy arterial wall (differential cutting). High rotational
speeds facilitate longitudinal burr movement across calciﬁcAbbreviations
and Acronyms
BMS = bare-metal stent(s)
CABG = coronary artery
bypass graft surgery
DES = drug-eluting stent(s)
ISR = in-stent restenosis
IVUS = intravascular
ultrasound
MACE = major adverse
cardiovascular events
MI = myocardial infarction
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
RA = rotational atherectomylesions by orthogonal displace-
ment of friction. A guidewire
helps to keep the burr’s abrasive tip
coaxial with the vessel lumen, al-
thoughwire bias in highly tortuous
or angulated segments may pre-
dispose to dissection or perfora-
tion. The guidewire should be
positioned distal to the target
lesion in the largest distal vessel,
avoiding small side branches and
distal narrow vasculature, and
avoiding bends, kinks, or loops.
Unlike balloon angioplasty,
which tends to produce intimal
splits and medial dissections in
calciﬁed lesions, RA yields a rela-
tively smooth luminal surface with
cylindrical geometry and mini-mal tissue injury (Fig. 1) (5–7). Lumen enlargement, typically
larger than the largest burr used, occurs mainly by selective
ablation of inelastic plaque without signiﬁcant arterial
expansion (8). Lumina are not always cylindrical after RA. In
regions of tortuosity or eccentric plaque, crater or gutter for-
mation can occur (lesion bias). This may impede stent de-
ployment or yield lumen enlargement greater than burr size.
Friction between the burr and plaque generates heat. Heat
varies with technique from 2.6C using intermittent ablation
and permitting minimal decelerations (4,000 to 6,000 rpm),
to 13.9C using continuous ablation allowing excessive de-
celerations (14,000 to 18,000 rpm) in experimental
modeling (9). Along with microembolization of debris,
thermal injury may contribute to increased risk of peri-
procedural myocardial infarction (MI) and restenosis asso-
ciated with excessive decelerations (10). Modern technique,
favoring gradual, intermittent ablation with a pecking mo-
tion, aims to minimize decelerations and thermal injury.Slower burr speeds of 140,000 to 150,000 rpm further
reduce platelet aggregation associated with RA (11).
RA particulate must traverse coronary microvasculature
before clearance by the reticuloendothelial system. Micro-
vascular obstruction can cause reduced contractility in sub-
tended myocardium, slow-ﬂow/no-reﬂow, and MI. Most
particles are sufﬁciently small to permit ready passage;
98% are <10 mm, with a mean diameter of 5 mm, which is
smaller than normal mature erythrocytes (4). Strategies to
enhance microvascular clearance, including vasodilators,
short runs with a pecking motion (to preserve antegrade
ﬂow), and maintenance of arterial blood pressure, reduce the
risk of these complications (12–14). The fundamentals of
optimal technique are summarized in Table 1.
Prevention of Complications
Patients undergoing RA experience clinical complications
common to PCI, including vascular access complications,
stroke, MI, urgent coronary artery bypass graft surgery
(CABG), and death, as well as angiographic complications,
including dissection, perforation, short-term closure, side
branch loss, and the slow-ﬂow/no-reﬂow phenomenon (15).
Frequencies of these complications reported in recent series
of RA before DES implantation are presented in Table 2
(16–25). Additional complications of particular importance
to RA include vasospasm (1.6% to 6.6%) and burr entrap-
ment (0.5% to 1%).
Smaller burr sizing (burr-to-artery ratio <0.7) reduces
angiographic complications and periprocedural creatine
kinase-myocardial band release, with similar procedural and
angiographic success, compared with more aggressive sizing
(burr-to-artery ratio >0.7) (10,26). Smaller burrs permit use
of smaller guiding catheters and, in turn, smaller arterial
sheaths, fewer catheter and sheath exchanges, and fewer
vascular complications.
Smaller sheath sizes are associated with less major femoral
bleeding (27) and permit radial access, an established
bleeding avoidance strategy (28). Among patients under-
going RA, a recent retrospective experience shows compa-
rable rates of procedural success, procedure time, and patient
radiation exposure with radial access compared with femoral
access (29).
Use of fewer, smaller guiding catheters may limit RA-
associated stroke. In a series of 21,794 PCI hospitalizations
between 1994 and 2008, RA was more often used in cases
of PCI-associated stroke than in propensity-matched
controls (30). Stroke cases tended to involve larger catheters
and more catheter exchangesdfactors linked to mobiliza-
tion of aortic debris in a prior study (31). It is likely that
patient features also contribute to stroke risk, because pa-
tients undergoing RA are often also affected by a greater
burden of atherosclerosis, vascular calciﬁcation, and
advanced age.
Figure 1. OCT Findings Before and After RA
Optical coherence tomography (OCT) performed before (PRE) rotational atherectomy (RA) in a calciﬁed de novo lesion (left). Following (POST) RA (right),
OCT shows disruption of the arc of calciﬁcation, modest luminal enlargement, and a relatively smooth luminal border.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 4 , 2 0 1 4 Tomey et al.
A P R I L 2 0 1 4 : 3 4 5 – 5 3 Current Status of Rotational Atherectomy
347Slow-ﬂow and no-reﬂow during RA are believed to relate
to microvascular embolization of atherosclerotic debris and
associated thrombi. Strategies to prevent these phenomena
include antiplatelet therapy, scrupulous technique, and va-
sodilators. The beneﬁt of antiplatelet therapy was established
with the glycoprotein IIb/IIIa inhibitor abciximab (32).
Comparable rates of death, MI, and urgent coronary artery
bypass graft surgery (CABG) have since been reported with
the direct thrombin inhibitor bivalirudin (33). Vasodilators
used for the purpose of reducing slow-ﬂow and no-reﬂow,
alone or in combination as a “cocktail” (34), include aden-
osine, calcium antagonists, nitroglycerin, and nicorandil (not
available in the United States). A summary of strategies to
prevent and treat slow-ﬂow and no-reﬂow is presented in
Table 3.
Burrs are susceptible to entrapment. If the burr passes
distal to an incompletely ablated segment of lesion, proximal
movement is restricted by absence of diamond chips on the
back of the burr, prohibiting retrograde ablation. Use of
smaller burrs and a technique of gradual, intermittent burr
advancement may help avoid entrapment. The burr should
never be allowed to stop spinning within a lesion. During
ablation, the operator should be attentive to potentialTable 1. Fundamental Elements of Optimal RA Technique
Single burr with burr-to-artery ratio of 0.5 to 0.6
Rotational speed of 140,000 to 150,000 rpm
Gradual burr advancement using a pecking motion
Short ablation runs of 15 to 20 s
Avoidance of decelerations >5,000 rpm
Final polishing run
RA ¼ rotational atherectomy.warning signs, which may be visual (lack of smooth
advancement under ﬂuoroscopy), auditory (pitch changes
with variation in resistance encountered by burr), or tactile
(resistance in advancer knob or excessive driveshaft vibra-
tion). If entrapment occurs, timely action is required to
remove the entrapped burr. Sulimov et al. (35) among others
(36,37), recently divided catheter-based solutions into 2
general approaches: balloon angioplasty and deep catheter
intubation. In order to deliver additional interventional de-
vices, access may be obtained either via a second arterial
puncture or disassembly of the RA apparatus. If catheter-
based solutions are unsuccessful, surgical removal and
CABG are required.
Indications
The cardinal indication for RA is the calciﬁc lesion, which,
in the absence of plaque modiﬁcation, confers an increased
likelihood of procedural failure, stent underdeployment,
restenosis, and major complications (38). Retrospective
series of RA describe high rates of short-term procedural
success (range 93.4% to 98.6%), superior to rates reported
separately in the absence of preceding plaque modiﬁcation
(39–41).
Consideration of RA requires determining calciﬁcation
severity, because beneﬁts of RA are attenuated when calci-
ﬁcation is mild or absent. In practice, calciﬁcation severity is
customarily graded by qualitative assessment of angiog-
raphy, with severe calciﬁcation deﬁned by radio-opacities
noted without cardiac motion before contrast injection,
generally involving both sides of the arterial wall, and
moderate calciﬁcation deﬁned by densities noted only dur-
ing the cardiac cycle before contrast injection (42).
Table 2. Reported Complications of RA and DES Implantation
Trial/First Author



















ROTAXUS (16) 2013 120 1.7 1.7 0.8 5.8 3.3 1.7 d d 0.0
Abdel-Wahab
et al. (17)
2013 205 1.5 2.4 d d 4.4 0.5 d d 2.0
Naito et al. (18) 2012 233 0.0 1.3 d d 1.7 0.4 d d d
Benezet et al. (19) 2011 102 1.0 1.0 d d 2.9 0.0 d d d
Dardas et al. (20) 2011 184 0.0 d d d d d d d d
Garcia de Lara
et al. (21)
2010 50 4.0 14.0 0.0 d 2.0 2.0 2.0 4.0 0.0
Rathore et al. (22) 2010 391 1.0 6.9 0.0 d 5.9 2.0 0.3 3.6 2.6
Vaquerizo et al. (23) 2010 63 0.0 3.2 0.0 1.6 d d 1.6 d d
Furuichi et al. (24) 2009 95 0.0 3.2 d d 2.1 1.1 d d 1.1
Clavijo et al. (25) 2006 81 0.0 19.8 d d 1.9 d d d d
CABG ¼ coronary artery bypass graft surgery; DES ¼ drug-eluting stent(s); MI ¼ myocardial infarction; RA¼ rotational atherectomy.
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348Angiography is insensitive for detection of calciﬁcation in
comparison with intravascular ultrasound (IVUS), but
visible calciﬁcation on angiography predicts a larger arc of
calciﬁcation on IVUS (43). Intravascular imaging with
IVUS or optical coherence tomography (OCT) further
permits discrimination of superﬁcial (near the intima–lumen
interface) and deep (at the media/adventitia border) calcium
(44,45).
RA facilitates procedural success in PCI of complex
(American College of Cardiology/American Heart Associ-
ation types B2 and C) lesions (46,47), including chronic
total occlusions (48,49), ostial lesions (50–52), and bifur-
cation lesions, which may be associated with both bulky
plaque and vessel geometry unfavorable for stent deploy-
ment. Selected studies have demonstrated favorable long-
term results of a debulking strategy with RA or directional
atherectomy for chronic total occlusions (53), bifurcation
lesions (54,55), and side branch ostia, alone or in combi-
nation with the main vessel (56,57).Table 3. Potential Mechanisms of Slow-Flow/No-Reﬂow During
RA and Associated Strategies for Prevention and Treatment
Mechanism Therapeutic Strategy
Atheromatous debris embolism Small burr sizing
Intermittent ablation
Avoidance of signiﬁcant decelerations
Platelet activation, aggregation,
and lysis
Optimal antiplatelet therapy, including use
of a glycoprotein IIb/IIIa inhibitor
Microcirculatory vasospasm Vasodilators
Liberal use of ﬂush solution
Neurohumoral reﬂex
bradycardia
Atropine Temporary venous pacemaker




Vasopressors (in particular, phenylephrine)
Intra-aortic balloon counterpulsation
RA ¼ rotational atherectomy.Although studied previously for treatment of in-stent
restenosis (ISR) with favorable short-term and late out-
comes, in the DES era, RA has largely been supplanted
for this purpose by balloon angioplasty, drug-coated bal-
loons, cutting or scoring balloons, same or different DES,
vascular brachytherapy, or CABG (58). It is worth noting
that the beneﬁts of RA, when used for ISR, likely depend on
the mechanism of restenosisdan observation explaining the
discrepancy between the 2 randomized trials on the subject.
In ROSTER (Randomized Trial of Rotational Atherec-
tomy Versus Balloon Angioplasty for Diffuse In-Stent
Restenosis), which randomized 200 patients with IVUS-
conﬁrmed diffuse ISR to RA plus low-pressure balloon
dilation or to high-pressure balloon dilation alone, RA was
associated with a signiﬁcant reduction in intimal hyperplasia
area, repeat stenting (10% vs. 31%, p < 0.001), and target
lesion revascularization (32% vs. 45%, p ¼ 0.042) at a mean
follow-up of 12 months (59). By contrast, in the ARTIST
trial (Angioplasty Versus Rotational Atherectomy for
Treatment of Diffuse In-Stent Restenosis), which did not
exclude stent underexpansion by IVUS, RA was associated
with inferior stent expansion and a higher incidence of bi-
nary restenosis (65% vs. 51%, p ¼ 0.039) at 6 months (60).
It is intuitive that RA is most beneﬁcial for removal of
intimal hyperplasia and less effective for radial expansion of
an underexpanded stent. If RA is contemplated for use in
DES ISR, pre-treatment imaging with IVUS or OCT may
be warranted to ﬁrst elucidate the mechanism of restenosis.
The RA burr is capable of ablating metallic stent struts
and does so preferentially because of differential cutting.
This has permitted careful application of RA to treatment of
underexpanded or crushed stents embedded in obstructive,
calciﬁc lesions (61). Analysis of metallic particulate gener-
ated by stent ablation reveals particles similar in average size
to those generated by atheroablation, 5.6  3.6 mm (62),
with 95% <15 mm (63).
Table 4. Long-Term Outcomes After RA and DES Implantation
First Author
(Ref. #) Year Patients Follow-Up MACE, % Repeat Revascularization, % ST, %
Abdel-Wahab et al. (17) 2013 205 DES 15 months 17.7 9.9 TVR, 6.8 TLR 1.0
Mangiacapra et al. (72) 2012 104 DES 1 yr 12.0* 5 TVR* 3.0
83 BMS 23.5 12.3 TVR 4.9
Naito et al. (18) 2012 179 SES 630 days 14.8 6.8 TVR, 4.9 TLR
54 PES 625 days 13.7 11.8 TVR, 9.8 TLR
Benezet et al. (19) 2011 102 DES 15 months 12.7 8.8 TLR 2.9
Dardas et al. (20) 2011 184 DES 49 months 14.9 3.3 TVR, 2.8 TLR
Fujimoto et al. (73) 2010 54 DES 12 months
26 RA+ 11.5 TLR* 0
28 RA 35.7 TLR 7.1
Garcia de Lara et al. (21) 2010 50 DES 1 yr 6 (CV death) 6 TLR
Rathore et al. (22) 2010 391 DES 6–9 months 10.6 TLR* 0.8
125 BMS 25.0 TLR 0.8
Vaquerizo et al. (23) 2010 63 DES 15 months 9.5 4.8 TLR 2.8
Furuichi et al. (24) 2009 96 DES 15 months 15.8 11.6 TVR, 9.5 TLR 4.2
Tamekiyo et al. (74) 2009 79 DES 2 yrs 30.1* 25.0 TLR*
144 BMS 43.1 39.1 TLR
Clavijo et al. (25) 2006 150 DES 6 months (Death)
81 RA+ 6.8 4.2
69 RA– 7.9 4.9
*Statistically signiﬁcant.
BMS ¼ bare-metal stent(s); CV ¼ cardiovascular; MACE ¼ major adverse cardiovascular events; PES ¼ paclitaxel-eluting stent(s); RAþ ¼
rotational atherectomy used; RA ¼ rotational atherectomy not used; ST ¼ stent thrombosis; SES ¼ sirolimus-eluting stent(s); TLR ¼ target lesion
revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 2.
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349Labeled contraindications to RA include saphenous vein
graft lesions, thrombus, dissection, and occlusions through
which a guidewire will not pass. Relative contraindications
include unavailability of bypass surgery (whether due to
patient ineligibility or lack of cardiac surgery on site), severe
3-vessel or unprotected left main disease, severe left ven-
tricular dysfunction, lesion length in excess of 25 mm, and
lesion angulation in excess of 45.
Exceptional reports of successful use of RA despite con-
traindications exist in recent literature, such as for cases of
severely calciﬁed nondilatable saphenous vein graft lesions
(64), iatrogenic coronary artery dissection (65,66), residual
nondilatable plaque after stent delivery in a case of acute MI
(67), and calciﬁed unprotected left main lesions in patients
deemed ineligible for bypass surgery (68). Use of RA in the
presence of 1 or more high-risk features has been associated
with more slow-ﬂow (30% vs. 18%, p ¼ 0.06) and peri-
procedural MI (8.8% vs. 2.1%, p ¼ 0.04) (69).
Outcomes
Prior reviews summarizing outcomes of RA in conjunction
with angioplasty and stenting have emphasized experience
with bare-metal stents (BMS) (15,70). Today, DES account
for most implanted stents (71). In broad populations, the
beneﬁts of DES above BMS for reduction in restenosis are
well established. Over the last 5 years, several case series havereported intermediate and long-term outcomes after DES
with adjunctive RA (Table 4) (17–25,72–74). Most of these
studies report rates of target lesion revascularization <10%
within 1 to 2 years.
DES are associated with improved outcomes after RA.
In patients treated with RA, rates of MACE are lower
with DES compared with BMS in 3 recent series
(22,72,74). This difference was primarily driven by less
repeat revascularization. This ﬁnding is consistent with
broader trials of DES versus BMS (75,76) and propensity-
matched comparison of DES versus BMS in patients with
calciﬁed lesions in the National Heart, Lung, and Blood
Institute’s Dynamic Registry (38).
It is unclear, however, whether RA improves outcomes
with DES. In theory, preparation of a smooth cylindrical
lumenmight facilitate superior stent deployment and, in turn,
reduced restenosis. This beneﬁt has not yet been shown.
Results are inconsistent in observational studies (25,73) and
difﬁcult to interpret because of selection biases inﬂuencing
assignment to RA (calciﬁcation, disease severity), which may
independently inﬂuence outcomes. Long-term beneﬁt was
again absent in the recent ROTAXUS (Rotational Athe-
rectomy Prior to Taxus Stent Treatment for Complex Native
Coronary Artery Disease) study, the ﬁrst randomized trial to
directly test the impact of RA on long-term outcomes of DES
placement (16). In a series of 240 patients with moderately or
severely calciﬁed obstructive lesions treated with or without
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350RA before paclitaxel-eluting stent implantation, there was
greater strategy success and short-term lumen gain with RA.
However, routine angiographic follow-up at 9 months
showed no difference in MACE and greater late lumen loss
(77) with an RA strategy. ROTAXUS had limitations,
including missing angiographic follow-up in 1 in 5 patients,
insufﬁcient power to compare clinical outcomes, a prepon-
derance of moderately calciﬁed lesions, and confounding
factors in the RA group that may have offset putative beneﬁts
of RA, such as longer lesion length and lower maximum pre-
dilation balloon pressure. Nonetheless, the authors’ conclu-
sions are appropriate that there is a continued lack of evidenceFigure 2. Proposed Algorithm for Use of Rotational or Orbital Atherectomy in Ma
In patients with de novo calciﬁed lesions for whom PCI is indicated clinically, lesion mo
procedural success when calciﬁcation is severe. If calciﬁcation severity is intermediate
be useful for reclassiﬁcation. CABG ¼ coronary artery bypass graft surgery; FFR ¼ fra
tomography; PCI ¼ percutaneous coronary intervention.to recommend RA as a routine lesion modiﬁcation strategy
before DES implantation in calciﬁed lesions.
Appropriate Use
Over the past 5 years, seminal clinical trials have shaped
understanding of the appropriate use of PCI in stable
ischemic heart disease, addressing scenarios of complex cor-
onary anatomy and comorbid diabetes mellitus (78–81). We
view RA as a tool to make PCI possible in complex lesions
with moderate or severe calciﬁcation when clinical variables
make PCI appropriate. An algorithm for application ofnagement of de Novo Calciﬁed Lesions
diﬁcation via rotational or orbital atherectomy is appropriate in order to facilitate
or indeterminate by angiography, intravascular imaging with IVUS or OCT may
ctional ﬂow reserve; IVUS ¼ intravascular ultrasound; OCT ¼ optical coherence
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351RA in clinical practice is presented in Figure 2. Of note,
when the severity of calciﬁcation is indeterminate at angio-
graphy, IVUS or OCT may be useful for reclassiﬁcation.
In select high-risk cases, mechanical circulatory assistance
may be warranted. It is important to recognize that use of
a mechanical circulatory assist device does not constitute
a license for unfettered RA. In the PROTECT II study
(Protect II, A Prospective, Multicenter Randomized
Controlled Trial of the IMPELLA RECOVER LP 2.5
System Versus Intra Aortic Balloon Pump [IABP] in Pa-
tients Undergoing Non Emergent High Risk PCI), which
randomized 452 symptomatic patients with complex disease
and severe left ventricular dysfunction to intra-aortic balloon
counterpulsation or the Impella 2.5 (Abiomed, Danvers,
Massachusetts) axial ﬂow rotary blood pump during elective
PCI, more extensive RA in the Impella group was associated
with an increased risk of major adverse events, driven by
periprocedural non–Q-wave MI (82).
For patients with ISR, RA is advisable only as a second
choice in select cases. RA may be useful when a lesion
cannot be crossed with a balloon, or when multiple jailed
side branches exist, using plaque debulking to minimize
“snow plow” plaque displacement in the context of balloon
dilation. In cases where metallic stent struts contribute
directly to luminal obstruction, RA may be utilized for
stent ablation. Otherwise, non-RA strategies, such as high-
pressure balloon, drug-coated balloon, or cutting balloon
dilation, are preferred, especially for cases of stent
underexpansion.Conclusions and Directions for Future Research
Literature from the inception of RA has consistently
demonstrated the utility of RA in facilitating procedural
success in treatment of calciﬁed, complex lesions. The safety
of doing so has improved with accumulated experience and
maturation of technique, including the opportunity to
further reduce complications with increased use of smaller
burrs and guiding catheters, fewer catheter exchanges, and
radial arterial access. We believe that RA remains an integral
tool to permit optimal angiographic outcomes in treatment
of complex coronary disease involving moderately to severely
calciﬁed lesions.
Evidence has yet to demonstrate that routine RA before
DES reduces restenosis. Long-term follow-up from the
ROTAXUS trial may offer additional insights. It is possible
that the impact of RA on repeat revascularization is most
pronounced for a subset of heavily calciﬁed lesions. Beyond
angiographic examination, IVUS or OCT may prove useful
in identifying features of plaque morphology predictive of
beneﬁt. Further research is also needed to clarify the utility
of combining RA with other modalities such as cutting or
drug-coated balloons in treatment of calciﬁc lesions (83).Pivotal trials in acute coronary syndromes over the past 5
years have led to introduction of novel antiplatelet agents,
including prasugrel and ticagrelor. Use has extended in
clinical practice to elective PCI. The impact of the new
agents on complications of RA is unknown and merits
study.
The persistence of angiographic and clinical complica-
tions of RA underscores the potential for further progress in
technology and technique. New devices are in development,
including a novel RA device to reduce microcavitation (84)
and an orbital atherectomy system for use with coronary
lesions. Distinct from RA, orbital atherectomy works on the
principle of elliptical burr movement, with variation in
effective burr size based on rotational speed. An orbital
atherectomy system has shown promise in preliminary
studies (85). Use of bivalirudin as the anticoagulant of choice
may further reduce bleeding complications of RA, although
further data are needed to establish this beneﬁt in the RA
setting and to conﬁrm equivalent efﬁcacy for prevention of
slow-ﬂow/no-reﬂow (33).
Finally, global declines in volume of coronary revascu-
larization, in particular PCI for stable ischemic heart disease
(86), will further reduce the already uncommon use of RA.
This will have important implications for efﬁcacy and safety
of RA, a technically demanding procedure reliant on oper-
ator experience. We believe the solution to this problem will
be to maintain referral centers of excellence for PCI of
complex lesions, including RA.
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